KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Liabilities (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Total Liabilities data on record, last reported at $216.3 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 16.53% year-over-year to $216.3 million; the TTM value through Sep 2025 reached $216.3 million, down 16.53%, while the annual FY2024 figure was $243.1 million, 8.96% down from the prior year.
  • Total Liabilities reached $216.3 million in Q3 2025 per NKTR's latest filing, down from $231.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $475.7 million in Q3 2021 and bottomed at $216.3 million in Q3 2025.
  • Average Total Liabilities over 5 years is $329.9 million, with a median of $297.3 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 40.87% in 2021, then dropped 26.27% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $437.7 million in 2021, then dropped by 21.41% to $344.0 million in 2022, then dropped by 22.36% to $267.0 million in 2023, then decreased by 8.96% to $243.1 million in 2024, then dropped by 11.05% to $216.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $216.3 million in Q3 2025, $231.7 million in Q2 2025, and $242.5 million in Q1 2025.